FDA Bioterrorism Efforts Could Delay Rulemakings, Guidance Documents
This article was originally published in The Tan Sheet
Executive Summary
FDA's non-user fee activities, such as developing rules and guidances, may be pushed back due to the agency's bioterrorism response efforts, Office of Training & Communications Director Nancy Smith suggested Nov. 5
You may also be interested in...
CDER Deputy Director Galson To Head Drug Center For Several Months
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
CDER Deputy Director Galson To Head Drug Center For Several Months
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months
CDER Deputy Director Galson To Head Drug Center For Several Months
Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, will serve as the center's acting director for the next several months